7 Biotechnology Companies in Austin to Know

Do not index

The most popular advice about biotechnology companies in Austin is to treat the city as one unified startup cluster and work through a directory from top to bottom. That approach hides the decision that matters most. Austin companies span clinical-stage therapeutics, drug-delivery technology, diagnostics, molecular testing, and outsourced formulation and manufacturing, so a therapeutic investor may be irrelevant to a diagnostics platform, while a CDMO may be more valuable to a founder than another equity financing conversation.

A practical screen starts with four questions: What type of company is this? What stage has it reached? Which operating capability can it provide? Which investors or partners understand that model? Austin's broader ecosystem has grown from about 25 life sciences companies in 2006 to nearly 300 by the late 2020s, according to local reporting on the city's life sciences expansion. The growth is meaningful, but the opportunity becomes clearer when you separate business models instead of counting logos.

The profiles below cover vertically integrated therapeutics, focused clinical development, enabling platforms, diagnostics, established molecular tools, and outsourced formulation and manufacturing. Each connects its operating model to partnership choices, fundraising questions, investor fit, advantages, risks, and a practical next step. Founders who need to protect research records while doing this work can also review this secure notebook for biotech researchers.

1. XBiotech

XBiotech represents a vertically integrated therapeutic company. Its “True Human” monoclonal antibodies are discovered directly from human donors, while discovery, process development, and cGMP manufacturing operate from a 48-acre Austin campus, according to XBiotech's company materials. Its pipeline addresses inflammatory and infectious diseases, giving the company a focused therapeutic identity rather than a broad platform claim.

The integrated model changes the diligence question. Founders, strategic partners, and investors are assessing whether one site can move a program from discovery through clinical-supply production with fewer external handoffs. That arrangement may reduce coordination with an outside CDMO, while placing more operational responsibility inside the company.

Why the model matters for founders

XBiotech offers a useful Austin case study in discovery-to-clinical-supply integration. A prospective partner should identify which capabilities are available for collaboration, how manufacturing capacity is allocated across programs, and whether the proposed relationship concerns technology, process development, clinical supply, or capital. Each area involves different decision-makers and partnership terms.

The company is clinical stage and has no approved products, so clinical and execution risk should shape any assessment. Its concentration in inflammatory and infectious disease programs may create depth, but it also limits near-term diversification compared with a multi-modality platform.

For founders building an investor list, relevant targets include biotech investors with antibody, clinical development, and translational manufacturing theses. The outreach question is whether the need is capital, manufacturing support, or a translational collaboration. Those objectives call for different evidence and different contacts. Use XBiotech's published program disclosures to verify current programs and operating details, then compare those capabilities with the portfolios in biotechnology investors in the United States. The practical next step is a one-page fit memo that states which relationship the founder is seeking. Avoid sending the same pitch for all three.

2. Savara Inc.

Savara focuses on clinical development in rare respiratory disease, with no in-house manufacturing story. The Austin-headquartered public biopharma develops inhaled therapies for conditions including autoimmune pulmonary alveolar proteinosis. Its corporate materials describe a pulmonary specialty pharmaceutical focus, placing the company in the focused clinical-development category rather than the vertically integrated therapeutics group.

That specialization can create value for partners with relevant expertise. Rare respiratory programs require disease-area knowledge, patient identification, trial design, regulatory planning, and experience with inhaled delivery. Founders should assess whether Savara's clinical network, respiratory focus, or delivery experience matches a specific collaboration objective. The location matters less than the operating overlap.

What to test before outreach

Savara's public-company status gives investors and potential partners access to SEC reporting and a more visible disclosure framework than a private early-stage company typically provides. Those materials can support diligence on program milestones, financing needs, and execution risk before an introductory conversation. They do not resolve clinical uncertainty. A concentrated portfolio can produce binary outcomes, while the absence of approved products may limit commercial revenue until approval.

Savara's Austin base may support relationships with regional academic and clinical institutions. Geographic proximity alone, however, does not establish partnership fit. A respiratory diagnostics company, inhaled-device developer, or clinical-trial service provider needs to connect its capabilities to a defined program requirement, decision-maker, and potential transaction.

Investor and partner fit

Savara aligns most closely with clinical-stage biotech investors, rare-disease specialists, pulmonary experts, and public-market healthcare investors. It offers founders developing inhaled or orphan-disease programs a useful comparable for a focused clinical model. The comparison can clarify whether a company is raising capital for a defined therapeutic program, seeking a development partner, or building evidence for a future transaction.

Start from Savara's published disease-area and delivery disclosures, identify the relevant overlap, and then use biopharma investors in the United States to build a thesis-specific list. State the clinical or pulmonary capability your company contributes, then specify what it needs from each recipient. A disease-area reference has limited value without a defined collaboration path, financing rationale, or next diligence step.

3. TFF Pharmaceuticals

TFF Pharmaceuticals represents the enabling-platform opportunity in Austin. Developed at UT Austin, its Thin Film Freezing technology converts small molecules, biologics, and vaccines into thermostable dry powders, with particular relevance to inhaled delivery. The TFF Pharmaceuticals platform overview describes applications addressing solubility, stability, and formulation constraints.

TFF monetises formulation capability across partner programs rather than a single disease thesis. Its opportunity therefore depends on whether the technology can solve delivery or formulation problems for specific assets. That model broadens the potential partnership set, while making validation program-specific. A successful result with one molecule does not establish equivalent performance for every biologic, vaccine, or inhaled product.

Questions for technology diligence

Founders assessing a platform partnership should establish which development stages TFF supports, what technical evidence exists for the relevant modality, and how work is divided between TFF and the asset owner. The proposed structure also needs definition. It could involve sponsored research, licensing, formulation services, or co-development, with different implications for ownership, funding, timelines, and decision rights.

A dry-powder formulation may reduce reliance on cold-chain logistics and improve patient convenience in suitable applications. These are potential operating advantages, not universal outcomes. The commercial case still rests on formulation performance, clinical validation, regulatory acceptance, and the partner's willingness to advance or license the resulting program.

TFF's UT Austin origins and collaborations make it relevant to founders connecting academic technology with product development. Its investor fit includes therapeutics investors with platform theses, drug-delivery specialists, licensing teams, and strategic pharmaceutical partners. Establish the platform's current scope from TFF's published modality data, then compare relevant investors through therapeutics investors in the United States. The next outreach asset should be a modality-specific partner brief naming the molecule or biologic, the formulation problem, the evidence available, and the milestone the relationship would target.

4. Everly Health

Everly Health, known to consumers through the Everlywell brand, represents the consumer diagnostics and digital-health infrastructure model. The Austin-headquartered company offers at-home laboratory test kits with clinician oversight, while Everly Health Solutions supports business-to-business testing and telehealth infrastructure. Its official company site describes an operating model built around specimen collection, testing services, and virtual-care workflows.

That model gives founders a practical comparison point across several businesses. A company developing home-collection services, virtual-care testing workflows, employer health products, or laboratory-access platforms may find relevant operational parallels. A novel-drug developer should evaluate Everly Health through a different lens, focusing on distribution, care delivery, and diagnostic workflow rather than therapeutic pipeline similarity.

The diligence lens is operational

Potential partners should map how patient ordering, clinician oversight, specimen collection, laboratory processing, result delivery, and follow-up care connect. Everly Health works with CLIA-certified laboratory partnerships, so diligence should examine the complete path from online purchase to clinical or commercial use. The test itself is only one component of the product.

At-home access can reduce friction for consumers and digital-health partners, while clinical utility depends on the test and its context. Founders should define the decision the test is intended to support, specify the clinician's role, and identify the evidence required for the target market. This analysis helps distinguish a convenient ordering channel from a diagnostic product with a credible care pathway.

For fundraising, Everly Health is most relevant to health diagnostics, digital-health, virtual-care, and healthcare infrastructure investors. Its U.S. operating scale and Austin presence provide a useful commercial reference, while founders still need to test demand, regulatory requirements, reimbursement assumptions, and delivery economics for their own category.

The next outreach asset should be a workflow map showing who orders, collects, processes, interprets, and acts on the result. It should also identify the operating partner required at each stage and the milestone that a prospective investor or commercial partner would help reach. Review the published workflow documentation, then use health diagnostics investors in the United States to find investors whose portfolios reflect diagnostics or healthcare delivery.

5. Asuragen

Asuragen represents an established molecular-tools and diagnostics business, not a venture-backed consumer startup. Founded in Austin and now a Bio-Techne brand, it is associated with AmplideX assays, genetics and oncology testing kits, companion analysis software, and products for clinical and research laboratories. The Asuragen product site offers the clearest starting point for reviewing its portfolio.

Its ownership structure affects partnership strategy. Asuragen maintains an Austin manufacturing and operations footprint within Bio-Techne, while the parent company contributes resources and distribution. A startup should define the required relationship before making contact: assay technology, reagent access, sequencing compatibility, distribution, or a commercial channel. A broad statement such as “we work in molecular diagnostics” does not establish a specific fit.

An infrastructure comparison

Asuragen's partnerships with sequencing platforms such as Oxford Nanopore place it within a broader laboratory and technology ecosystem. For founders developing genetic assays or translational tools, that makes the company a useful benchmark for platform adoption. The relevant question is whether an assay improves a defined laboratory workflow, works with existing instrumentation, and can be supported by credible commercial and quality operations.

Clinical and research laboratories buy through processes that include validation, procurement, training, and ongoing support. Founders moving from academic proof of concept to laboratory adoption should account for these requirements early. Distribution alone does not create repeatable demand.

Bio-Techne ownership may broaden market access, while product purchasing and partnership discussions may operate through parent-company systems. Founders should identify the appropriate business unit and decision-maker before outreach. The practical next step is to map the assay to a specific AmplideX or related workflow, then request a narrowly defined technical or commercial discussion. This positions Asuragen as a potential enabling-platform or channel partner, rather than treating it like an early-stage therapeutics company. Diligence should therefore focus on workflow fit, quality readiness, channel ownership, and the milestone a partnership would advance.

6. Luminex

Luminex represents established multiplexing infrastructure, not an early-stage assay concept seeking its first deployment. Now a DiaSorin company, it is known for xMAP and xTAG multiplex platforms used in clinical and research applications. The DiaSorin site provides the appropriate corporate entry point for current product, support, and company information.

Its value comes from the combination of technology, an installed ecosystem, assay partners, training, field service, and operational support. Luminex's Austin site supports laboratory users, while DiaSorin adds global distribution and corporate infrastructure. For founders, this creates a build-versus-integrate decision. Building an independent diagnostic workflow may preserve control, but connecting to an established instrument-and-reagent network can provide a clearer route to laboratory adoption.

What founders should compare

A diagnostics company assessing Luminex should examine instrument compatibility, assay development requirements, validation workload, field support, and the cost of operating within an existing platform ecosystem. The platform can connect an assay to established laboratory workflows, although adoption still depends on analytical performance, procurement requirements, service quality, and the customer's installed equipment.

That distinction affects investor fit. Luminex is a platform and infrastructure comparable, whereas a company built around one novel biomarker presents a different diligence case. Investors should ask whether recurring laboratory use, partner assays, and service operations create a durable commercial position, or whether the proposed product depends on a narrow integration opportunity.

Luminex is primarily B2B. Its buyers are laboratories and healthcare organizations, so outreach should identify technical, commercial, or partnership owners rather than rely on general corporate contacts. DiaSorin's corporate structure may make ownership of a specific request less obvious.

The next step is to document the exact integration point: sample type, assay or instrument requirement, laboratory user, validation need, and commercial outcome. Then approach Luminex or DiaSorin through the corporate partnership route described on the DiaSorin site referenced above, rather than sending a broad partnership pitch.

7. AustinPx

AustinPx is the outsourced formulation and manufacturing partner in this group. Formerly DisperSol Technologies, the Austin-area CDMO develops formulations and manufactures oral solid dosage products, including KinetiSol-based technologies intended to improve the solubility of poorly soluble drugs. Its AustinPx website describes support from preclinical work through early clinical GMP supply.

Its operating model suits founders with a promising compound but without formulation expertise, process-development capacity, equipment, or quality systems for early clinical supply. AustinPx is therefore an operating partner, not a therapeutic owner or an equity comparable. For investors and accelerators, the diligence question is whether outsourcing advances a defined milestone without creating avoidable dependence on a vendor.

The founder's decision

Technical fit should determine the relationship. Founders should assess the molecule, dosage form, development stage, and milestone first, then ask about formulation fit, analytical methods, batch expectations, quality documentation, technology transfer, and scheduling. Those answers shape partnership terms, financing needs, and the timing of future manufacturing decisions.

KinetiSol and related enabling technologies may help poorly soluble compounds, but program-specific evidence still matters. A differentiated technology is useful only if the formulation improves the asset's development path and can become a manufacturable product. Investors should separate platform promise from evidence generated for the individual program.

AustinPx serves Texas and national clients, and its experience translating academic technologies into products may fit university spinouts and early biotech teams. Capacity and timelines can fluctuate with demand, so vendor diligence should begin before a clinical deadline. A practical outreach package should state the compound, target dosage form, current data, required development milestone, and expected GMP need.

Austin Biotechnology Companies, 7-Company Comparison

Item	🔄 Implementation complexity	⚡ Resource requirements	⭐📊 Expected outcomes	💡 Ideal use cases	⭐ Key advantages
XBiotech	High 🔄, integrated discovery, process dev & cGMP on one site	High ⚡, large campus, manufacturing equipment, regulatory compliance	Moderate ⭐📊, faster translation potential but clinical‑stage risk (no approvals)	💡 Partners/investors wanting vertical integration and on‑site clinical supply	⭐ Vertical integration and single‑site discovery→clinical supply
Savara Inc.	Moderate 🔄, inhaled therapy development with clinical programs	Moderate ⚡, focused R&D and clinical trial resources; public reporting	Moderate ⭐📊, high binary clinical risk; potential orphan approvals	💡 Inhaled/orphan‑disease developers or investors seeking public transparency	⭐ Pulmonary specialization and Austin HQ with experienced leadership
TFF Pharmaceuticals	Moderate 🔄, platform formulation and scale‑up for dry powders	Moderate ⚡, formulation labs, collaboration/licensing model	Moderate ⭐📊, enables thermostable dry powders; outcomes partner‑dependent	💡 Partners needing inhaled delivery, dry‑powder vaccines or cold‑chain reduction	⭐ Thin Film Freezing platform adaptable across modalities
Everly Health (Everlywell)	Low‑Moderate 🔄, consumer diagnostics plus CLIA/B2B operations	Moderate ⚡, logistics, CLIA lab partnerships, telehealth infrastructure	Moderate ⭐📊, broad consumer reach and B2B scale; variable clinical utility by test	💡 At‑home testing, virtual care integrations, consumer‑facing diagnostics	⭐ Convenient at‑home access and established digital‑health platform
Asuragen (Bio‑Techne)	Moderate 🔄, assay kit dev and integration with parent company systems	Moderate ⚡, manufacturing, validation, platform partnerships	High ⭐📊, validated genetic assays widely used in clinical/research labs	💡 Labs and translational researchers needing validated genetic assays	⭐ Established products backed by Bio‑Techne and platform partnerships
Luminex (DiaSorin)	Moderate‑High 🔄, instrument platforms, multiplex assay ecosystem	High ⚡, instruments, reagents, global service/training capabilities	High ⭐📊, broad lab adoption and multiplex testing capacity	💡 Clinical/research labs needing multiplex immunoassay or molecular platforms	⭐ Proven xMAP/xTAG tech and large partner ecosystem
AustinPx (DisperSol)	Moderate 🔄, CDMO formulation & GMP manufacturing for oral dosage	Moderate ⚡, formulation expertise, KinetiSol tech, scalable GMP capacity	Moderate ⭐📊, enables clients to reach clinical supply; dependent on client success	💡 Startups needing formulation & early clinical GMP supply without building internal ops	⭐ KinetiSol solubility expertise and client‑centric CDMO services

Turn the Directory Into a Fundraising Map

Austin's life sciences scale is large enough to support several distinct operating models. Recent ecosystem reporting places the region at more than 1,100 bio and health companies, a total valuation of 100 million, according to the Austin BioHealth ecosystem overview. Those figures describe density, not automatic fit. A founder still needs to identify where their company sits within that density.

The seven profiles form four practical paths. XBiotech and Savara belong with therapeutic and translational investors, although they represent different models. XBiotech emphasizes integrated antibody discovery and manufacturing, while Savara demonstrates focused pulmonary clinical development. TFF Pharmaceuticals belongs with platform, technology-transfer, and licensing investors because its value depends on applying formulation technology across partner programs rather than advancing one disease thesis alone.

Everly Health, Asuragen, and Luminex fit the diagnostics and life-science infrastructure group, but they shouldn't be treated as interchangeable. Everly Health centers on consumer access, B2B testing, and virtual-care infrastructure. Asuragen focuses on molecular assays and laboratory products within Bio-Techne. Luminex provides multiplexing technology, instruments, reagents, training, and support through DiaSorin. The buyer, validation path, and partnership decision-maker differ in each case.

AustinPx serves a different founder need entirely. It can be relevant when a startup needs formulation development or early clinical GMP manufacturing without building those capabilities internally. That makes it a development and execution partner, not a fundraising comparable.

Use this traction playbook for investors to frame evidence around the milestone that matters for your model, not around Austin's reputation. Then repeat the following process:

Define your category: Decide whether you're a therapeutic, diagnostic, platform, molecular-tools, or service business.

State your stage: Separate discovery, preclinical development, clinical development, laboratory adoption, and commercial operations.

Document your capability: Identify the specific technology, assay, manufacturing process, clinical insight, or distribution advantage that creates fit.

Shortlist comparable models: Compare your operating requirements with companies that sell to the same buyer or depend on the same milestone.

Build the investor list around evidence: Look for investors whose portfolios and thesis match your modality, disease area, customer, and stage, rather than selecting them because they're located in Austin.

Gritt.io can support the outreach workflow after that analysis is complete. Its portfolio-aware matching, approval-based personalized drafting, Gmail sending, and searchable investor directory help founders turn a validated fit list into controlled one-to-one outreach. It should be used to operationalize a clear thesis, not to replace scientific, regulatory, commercial, or investor diligence. Founders can review the platform at Gritt.io and avoid making unsupported assumptions about any company's fundraising history.

Gritt.io helps founders find relevant investors, draft portfolio-aware personalized emails, review every message before sending, and send approved outreach through Gmail. For a biotechnology company in Austin, use it after defining your category and milestone so your investor search reflects real operating fit. Visit Gritt.io to turn your shortlist into controlled outreach.